Nektar Therapeutics Board Grants Stock Options to New Employees
What happened
The board of directors of Nektar Therapeutics granted non-qualified stock options and restricted stock units to sixteen newly-hired employees on October 20, 2026, under the 2025 Inducement Plan. The grant included 45,750 shares of common stock and 2,775 restricted stock units. The plan was previously amended to increase the total shares reserved for issuance to 500,000.
From prnewswire.com
Why it matters
The grant of equity awards is part of Nektar Therapeutics' compensation strategy to attract new talent. The stock options have an exercise price of $39.22, which matches the common stock closing price on October 20, 2026.
From prnewswire.com
Who's involved
- Nektar TherapeuticsAmerican healthcare company receiving the equity grant
- board of directorsGroup that governed the grant of stock options to new employees
Keep exploring
The entities involved
-
Nektar Therapeutics
American healthcare company
Nothing else this week.
-
board of directors
group of people who jointly supervise the activities of an organization
Related events
- Mirasol Resources Ltd.'s board of directors approved an incentive stock options grant on October 23, 2026.
- Leerink Partners assumed coverage on Nektar Therapeutics shares on October 13, 2026.
- Aclarion's board of directors authorized a stock repurchase program on August 6, 2026.
- Jubilant Pharmova Limited's board approved the issuance of Non-Convertible Debentures (NCDs) proposed for listing on the BSE.
- Board of directors of DXP Enterprises, Inc. authorized a new stock repurchase program on October 28, 2026.